Novo Nordisk A/S
Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Metsera on Tuesday said Novo Nordisk‘s new […]
Read More
Pfizer tops estimates, raises profit guidance even as sales fall
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]
Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]
Read More
November trading, Berkshire’s cash hoard, Big Tech’s ad revenue and more in Morning Squawk
A trader works on the floor of the New York Stock Exchange on Oct. 30, 2025 in New York. Angela Weiss | AFP | Getty Images This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading day: 1. November […]
Read More
Where the blockbuster weight loss drug market stands today — and what’s coming next
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The appetite for blockbuster weight loss and diabetes drugs is far from satisfied. From fresh competition to new uses, the market is quickly vaulting into a new stage of […]
Read More
Global week ahead: Is Novo Nordisk past ‘peak uncertainty’?
At one point, it was Europe’s most valuable company. Now, as Danish pharmaceutical group Novo Nordisk prepares to publish its third-quarter earnings on Wednesday, the picture looks very different. Jonathan Raa | Nurphoto | Getty Images CNBC’s Charlotte Reed will travel to Copenhagen to speak with the company’s new CEO Mark Doustdar, a 30-year veteran […]
Read More
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s $8.5 billion bid for the U.S. obesity drug developer to be a superior offer. Pfizer asked the Delaware court where it filed the lawsuit to issue a temporary restraining order to […]
Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]
Read More
Novo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Denmark’s Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the fast-growing and competitive weight-loss drug market. Novo Nordisk, the company behind blockbuster weight loss drug Wegovy and diabetes […]
Read More
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster […]
Read More